Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 358

1.

Cardiovascular and sedation reversal effects of intramuscular administration of atipamezole in dogs treated with medetomidine hydrochloride with or without the peripheral α2-adrenoceptor antagonist vatinoxan hydrochloride.

Turunen H, Raekallio MR, Honkavaara JM, Restitutti F, Kallio-Kujala IJ, Adam M, Nevanperä K, Scheinin M, Männikkö SK, Hautajärvi HJ, Larenza Menzies P, Vainio OM.

Am J Vet Res. 2019 Oct;80(10):912-922. doi: 10.2460/ajvr.80.10.912.

PMID:
31556714
2.

Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study.

Lähdeaho ML, Scheinin M, Vuotikka P, Taavela J, Popp A, Laukkarinen J, Koffert J, Koivurova OP, Pesu M, Kivelä L, Lovró Z, Keisala J, Isola J, Parnes JR, Leon F, Mäki M.

Lancet Gastroenterol Hepatol. 2019 Sep 4. pii: S2468-1253(19)30264-X. doi: 10.1016/S2468-1253(19)30264-X. [Epub ahead of print]

PMID:
31494096
3.

Effects of vatinoxan on cardiorespiratory function, fecal output and plasma drug concentrations in horses anesthetized with isoflurane and infusion of medetomidine.

Tapio HA, Raekallio MR, Mykkänen AK, Al-Ramahi D, Scheinin M, Hautajärvi HJ, Männikkö S, Vainio O.

Vet J. 2019 Sep;251:105345. doi: 10.1016/j.tvjl.2019.105345. Epub 2019 Jul 27.

PMID:
31492389
4.

Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression.

Ponikwicka-Tyszko D, Chrusciel M, Stelmaszewska J, Bernaczyk P, Chrusciel P, Sztachelska M, Scheinin M, Bidzinski M, Szamatowicz J, Huhtaniemi IT, Wolczynski S, Rahman NA.

EBioMedicine. 2019 Sep;47:170-183. doi: 10.1016/j.ebiom.2019.08.035. Epub 2019 Aug 26.

5.

Treating gambling disorder with as needed administration of intranasal naloxone: a pilot study to evaluate acceptability, feasibility and outcomes.

Castrén S, Mäkelä N, Haikola J, Salonen AH, Crystal R, Scheinin M, Alho H.

BMJ Open. 2019 Aug 21;9(8):e023728. doi: 10.1136/bmjopen-2018-023728. Erratum in: BMJ Open. 2019 Sep 13;9(9):e023728corr1.

6.

Upper Airway Collapsibility during Dexmedetomidine and Propofol Sedation in Healthy Volunteers: A Nonblinded Randomized Crossover Study.

Lodenius Å, Maddison KJ, Lawther BK, Scheinin M, Eriksson LI, Eastwood PR, Hillman DR, Fagerlund MJ, Walsh JH.

Anesthesiology. 2019 Aug 9. doi: 10.1097/ALN.0000000000002883. [Epub ahead of print]

PMID:
31403974
7.

Pharmacokinetics and Sedative Effects of Intranasal Dexmedetomidine in Ambulatory Pediatric Patients.

Uusalo P, Guillaume S, Siren S, Manner T, Vilo S, Scheinin M, Saari TI.

Anesth Analg. 2019 Jun 12. doi: 10.1213/ANE.0000000000004264. [Epub ahead of print]

PMID:
31206433
8.

Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects.

Johansson J, Hirvonen J, Lovró Z, Ekblad L, Kaasinen V, Rajasilta O, Helin S, Tuisku J, Sirén S, Pennanen M, Agrawal A, Crystal R, Vainio PJ, Alho H, Scheinin M.

Neuropsychopharmacology. 2019 Aug;44(9):1667-1673. doi: 10.1038/s41386-019-0368-x. Epub 2019 Mar 13.

PMID:
30867551
9.

Effects of vatinoxan on cardiorespiratory function and gastrointestinal motility during constant-rate medetomidine infusion in standing horses.

Tapio H, Raekallio MR, Mykkänen A, Männikkö S, Scheinin M, Bennett RC, Vainio O.

Equine Vet J. 2019 Sep;51(5):646-652. doi: 10.1111/evj.13085. Epub 2019 Mar 14.

10.

Premedication with intranasal dexmedetomidine decreases barbiturate requirement in pediatric patients sedated for magnetic resonance imaging: a retrospective study.

Uusalo P, Lehtinen M, Löyttyniemi E, Manner T, Scheinin M, Saari TI.

BMC Anesthesiol. 2019 Feb 13;19(1):22. doi: 10.1186/s12871-019-0690-1.

11.

Radiosynthesis and Preclinical Evaluation of an α2A-Adrenoceptor Tracer Candidate, 6-[18F]Fluoro-marsanidine.

Krzyczmonik A, Keller T, López-Picón FR, Forsback S, Kirjavainen AK, Takkinen JS, Wasilewska A, Scheinin M, Haaparanta-Solin M, Sączewski F, Solin O.

Mol Imaging Biol. 2019 Oct;21(5):879-887. doi: 10.1007/s11307-019-01317-6.

PMID:
30710261
12.

Effects of dexmedetomidine and MK-467 on plasma glucose, insulin and glucagon in a glibenclamide-induced canine hypoglycaemia model.

Kallio-Kujala IJ, Bennett RC, Raekallio MR, Yatkin E, Meierjohann A, Savontaus E, Scheinin M, Spillmann T, Vainio OM.

Vet J. 2018 Dec;242:33-38. doi: 10.1016/j.tvjl.2018.09.012. Epub 2018 Sep 21.

13.

Effects of the peripherally acting α2-adrenoceptor antagonist MK-467 on cardiopulmonary function in sheep sedated by intramuscular administration of medetomidine and ketamine and reversed by intramuscular administration of atipamezole.

Adam M, Raekallio MR, Salla KM, Honkavaara JM, Männikkö S, Scheinin M, Kajula M, Mölsä SH, Vainio OM.

Am J Vet Res. 2018 Sep;79(9):921-932. doi: 10.2460/ajvr.79.9.921.

PMID:
30153057
14.

Increased Energy Expenditure, Lipolysis and Hyperinsulinemia Confer Resistance to Central Obesity and Type 2 Diabetes in Mice Lacking Alpha2α-Adrenoceptors.

Ruohonen ST, Valve L, Tuomainen K, Ailanen L, Röyttä M, Manz G, Baur N, Joos TO, Savontaus E, Scheinin M.

Neuroendocrinology. 2018;107(4):324-339. doi: 10.1159/000492387. Epub 2018 Jul 24.

PMID:
30041171
15.

Peripheral α2-adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs.

Kallio-Kujala IJ, Raekallio MR, Honkavaara J, Bennett RC, Turunen H, Scheinin M, Hautajärvi H, Vainio O.

Vet Anaesth Analg. 2018 Jul;45(4):405-413. doi: 10.1016/j.vaa.2018.01.008. Epub 2018 Feb 3.

PMID:
29891212
16.

Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers.

Uusalo P, Al-Ramahi D, Tilli I, Aantaa RA, Scheinin M, Saari TI.

Eur J Clin Pharmacol. 2018 Aug;74(8):1047-1054. doi: 10.1007/s00228-018-2461-1. Epub 2018 Apr 17.

PMID:
29666901
17.

Effect of oral KETOPROFEN treatment in acute respiratory disease outbreaks in finishing pigs.

Hälli O, Haimi-Hakala M, Laurila T, Oliviero C, Viitasaari E, Orro T, Peltoniemi O, Scheinin M, Sirén S, Valros A, Heinonen M.

Porcine Health Manag. 2018 Mar 6;4:7. doi: 10.1186/s40813-018-0081-x. eCollection 2018.

18.

Sedative Plasma Concentrations and Delirium Risk in Critical Illness.

Stollings JL, Thompson JL, Ferrell BA, Scheinin M, Wilkinson GR, Hughes CG, Shintani AK, Ely EW, Girard TD, Pandharipande PP, Patel MB.

Ann Pharmacother. 2018 Jun;52(6):513-521. doi: 10.1177/1060028017753480. Epub 2018 Jan 24.

19.

The impact of MK-467 on plasma drug concentrations, sedation and cardiopulmonary changes in sheep treated with intramuscular medetomidine and atipamezole for reversal.

Adam M, Raekallio MR, Keskitalo T, Honkavaara JM, Scheinin M, Kajula M, Mölsä S, Vainio OM.

J Vet Pharmacol Ther. 2018 Jun;41(3):447-456. doi: 10.1111/jvp.12486. Epub 2018 Jan 19.

PMID:
29352473
20.

The role of active transport in the transcellular movement of the peripheral α2-adrenoceptor antagonist, MK-467: An in vitro pilot study.

Bennett R, Palviainen M, Peltoniemi M, Vuorilehto L, Scheinin M, Raekallio M, Vainio O.

Can J Vet Res. 2017 Oct;81(4):318-320.

21.

The effect of an apple polyphenol extract rich in epicatechin and flavan-3-ol oligomers on brachial artery flow-mediated vasodilatory function in volunteers with elevated blood pressure.

Saarenhovi M, Salo P, Scheinin M, Lehto J, Lovró Z, Tiihonen K, Lehtinen MJ, Junnila J, Hasselwander O, Tarpila A, Raitakari OT.

Nutr J. 2017 Oct 27;16(1):73. doi: 10.1186/s12937-017-0291-0.

22.

Cardiovascular effects of premedication with medetomidine alone and in combination with MK-467 or glycopyrrolate in dogs subsequently anesthetized with isoflurane.

Salla KM, Tuns CI, Bennett RC, Raekallio MR, Scheinin M, Kuusela E, Vainio OM.

Am J Vet Res. 2017 Nov;78(11):1245-1254. doi: 10.2460/ajvr.78.11.1245.

PMID:
29076369
23.

Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease.

Rinne JO, Wesnes K, Cummings JL, Hakulinen P, Hallikainen M, Hänninen J, Murphy M, Riordan H, Scheinin M, Soininen H, Rouru J.

Alzheimers Dement (N Y). 2016 Dec 8;3(1):1-9. doi: 10.1016/j.trci.2016.11.004. eCollection 2017 Jan.

24.

Effects of the α2-adrenoceptor agonist medetomidine on the distribution and clearance of alfaxalone during coadministration by constant rate infusion in dogs.

Bennett RC, Salla KM, Raekallio MR, Scheinin M, Vainio OM.

Am J Vet Res. 2017 Aug;78(8):956-964. doi: 10.2460/ajvr.78.8.956.

PMID:
28738010
25.

Gene expression profiles and signaling mechanisms in α2B-adrenoceptor-evoked proliferation of vascular smooth muscle cells.

Huhtinen A, Hongisto V, Laiho A, Löyttyniemi E, Pijnenburg D, Scheinin M.

BMC Syst Biol. 2017 Jun 28;11(1):65. doi: 10.1186/s12918-017-0439-8.

26.

Plasma concentration and cardiovascular effects of intramuscular medetomidine combined with three doses of the peripheral alpha2-antagonist MK-467 in dogs.

Restitutti F, Kaartinen MJ, Raekallio MR, Wejberg O, Mikkola E, Del Castillo JRE, Scheinin M, Vainio OM.

Vet Anaesth Analg. 2017 May;44(3):417-426. doi: 10.1016/j.vaa.2016.04.006. Epub 2017 Jan 11.

PMID:
28552594
27.

Safety, Tolerability, and Antihypertensive Effect of SER100, an Opiate Receptor-Like 1 (ORL-1) Partial Agonist, in Patients With Isolated Systolic Hypertension.

Kantola I, Scheinin M, Gulbrandsen T, Meland N, Smerud KT.

Clin Pharmacol Drug Dev. 2017 Nov;6(6):584-591. doi: 10.1002/cpdd.330. Epub 2016 Dec 29.

PMID:
28032481
28.

Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial.

Stenman LK, Lehtinen MJ, Meland N, Christensen JE, Yeung N, Saarinen MT, Courtney M, Burcelin R, Lähdeaho ML, Linros J, Apter D, Scheinin M, Kloster Smerud H, Rissanen A, Lahtinen S.

EBioMedicine. 2016 Nov;13:190-200. doi: 10.1016/j.ebiom.2016.10.036. Epub 2016 Oct 26.

29.

Sedation with Dexmedetomidine or Propofol Impairs Hypoxic Control of Breathing in Healthy Male Volunteers: A Nonblinded, Randomized Crossover Study.

Lodenius Å, Ebberyd A, Hårdemark Cedborg A, Hagel E, Mkrtchian S, Christensson E, Ullman J, Scheinin M, Eriksson LI, Jonsson Fagerlund M.

Anesthesiology. 2016 Oct;125(4):700-15. doi: 10.1097/ALN.0000000000001236.

PMID:
27483127
30.

A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin.

Vucicevic J, Srdic-Rajic T, Pieroni M, Laurila JM, Perovic V, Tassini S, Azzali E, Costantino G, Glisic S, Agbaba D, Scheinin M, Nikolic K, Radi M, Veljkovic N.

Bioorg Med Chem. 2016 Jul 15;24(14):3174-83. doi: 10.1016/j.bmc.2016.05.043. Epub 2016 May 24.

PMID:
27265687
31.

Transfer of SAR information from hypotensive indazole to indole derivatives acting at α-adrenergic receptors: In vitro and in vivo studies.

Sączewski J, Hudson A, Scheinin M, Wasilewska A, Sączewski F, Rybczyńska A, Ferdousi M, Laurila JM, Boblewski K, Lehmann A, Watts H, Ma D.

Eur J Med Chem. 2016 Jun 10;115:406-15. doi: 10.1016/j.ejmech.2016.03.026. Epub 2016 Mar 14.

PMID:
27031216
32.

Clinical effects and pharmacokinetic variables of romifidine and the peripheral α2 -adrenoceptor antagonist MK-467 in horses.

de Vries A, Pakkanen SA, Raekallio MR, Ekiri A, Scheinin M, Taylor PM, Vainio OM.

Vet Anaesth Analg. 2016 Nov;43(6):599-610. doi: 10.1111/vaa.12354. Epub 2016 Feb 26.

PMID:
26918855
33.

Differential Internalization Rates and Postendocytic Sorting of the Norepinephrine and Dopamine Transporters Are Controlled by Structural Elements in the N Termini.

Vuorenpää A, Jørgensen TN, Newman AH, Madsen KL, Scheinin M, Gether U.

J Biol Chem. 2016 Mar 11;291(11):5634-51. doi: 10.1074/jbc.M115.702050. Epub 2016 Jan 19.

34.

Effects of MK-467 on the antinociceptive and sedative actions and pharmacokinetics of medetomidine in dogs.

Bennett RC, Salla KM, Raekallio MR, Hänninen L, Rinne VM, Scheinin M, Vainio OM.

J Vet Pharmacol Ther. 2016 Aug;39(4):336-43. doi: 10.1111/jvp.12292. Epub 2016 Jan 14.

PMID:
26763145
35.

Detecting a dexmedetomidine-evoked reduction of noradrenaline release in the human brain with the alpha2C-adrenoceptor PET ligand [11C]ORM-13070.

Lehto J, Scheinin A, Johansson J, Marjamäki P, Arponen E, Scheinin H, Scheinin M.

Synapse. 2016 Feb;70(2):57-65. doi: 10.1002/syn.21872. Epub 2015 Nov 26.

PMID:
26562363
36.

Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects.

Yoo H, Iirola T, Vilo S, Manner T, Aantaa R, Lahtinen M, Scheinin M, Olkkola KT, Jusko WJ.

Eur J Clin Pharmacol. 2015 Oct;71(10):1197-207. doi: 10.1007/s00228-015-1913-0. Epub 2015 Aug 2.

PMID:
26233335
37.

Potentiation of Glibenclamide Hypoglycaemia in Mice by MK-467, a Peripherally Acting Alpha2-Adrenoceptor Antagonist.

Ruohonen ST, Ranta-Panula V, Bastman S, Chrusciel P, Scheinin M, Streng T.

Basic Clin Pharmacol Toxicol. 2015 Dec;117(6):392-8. doi: 10.1111/bcpt.12440. Epub 2015 Jul 30.

38.

Application of cross-species PET imaging to assess neurotransmitter release in brain.

Finnema SJ, Scheinin M, Shahid M, Lehto J, Borroni E, Bang-Andersen B, Sallinen J, Wong E, Farde L, Halldin C, Grimwood S.

Psychopharmacology (Berl). 2015 Nov;232(21-22):4129-57. doi: 10.1007/s00213-015-3938-6. Epub 2015 Apr 30. Review.

39.

Sensitivity of [(11)C]ORM-13070 to increased extracellular noradrenaline in the CNS - a PET study in human subjects.

Lehto J, Johansson J, Vuorilehto L, Luoto P, Arponen E, Scheinin H, Rouru J, Scheinin M.

Psychopharmacology (Berl). 2015 Nov;232(21-22):4169-78. doi: 10.1007/s00213-015-3941-y. Epub 2015 Apr 29.

PMID:
25918111
40.

Experimental evolution gone wild.

Scheinin M, Riebesell U, Rynearson TA, Lohbeck KT, Collins S.

J R Soc Interface. 2015 May 6;12(106). pii: 20150056. doi: 10.1098/rsif.2015.0056.

41.

Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.

Saarikoski T, Saari TI, Hagelberg NM, Backman JT, Neuvonen PJ, Scheinin M, Olkkola KT, Laine K.

Eur J Clin Pharmacol. 2015 Mar;71(3):321-7. doi: 10.1007/s00228-014-1799-2. Epub 2015 Jan 6.

PMID:
25560051
42.

Imaging of α2C-adrenoceptors in the living brain: a method to monitor noradrenaline release?

Scheinin M, Lehto J, Johansson J, Luoto P, Arponen E, Vuorilehto L, Scheinin H, Rouru J.

Springerplus. 2015 Jun 12;4(Suppl 1):L20. doi: 10.1186/2193-1801-4-S1-L20. eCollection 2015. No abstract available.

43.

Validation of [(11) C]ORM-13070 as a PET tracer for alpha2c -adrenoceptors in the human brain.

Lehto J, Hirvonen MM, Johansson J, Kemppainen J, Luoto P, Naukkarinen T, Oikonen V, Arponen E, Rouru J, Sallinen J, Scheinin H, Vuorilehto L, Finnema SJ, Halldin C, Rinne JO, Scheinin M.

Synapse. 2015 Mar;69(3):172-81. doi: 10.1002/syn.21798. Epub 2015 Jan 8.

PMID:
25530024
44.

Detomidine and the combination of detomidine and MK-467, a peripheral alpha-2 adrenoceptor antagonist, as premedication in horses anaesthetized with isoflurane.

Pakkanen SA, Raekallio MR, Mykkänen AK, Salla KM, de Vries A, Vuorilehto L, Scheinin M, Vainio OM.

Vet Anaesth Analg. 2015 Sep;42(5):527-36. doi: 10.1111/vaa.12238. Epub 2014 Dec 22.

PMID:
25529045
45.

Amphetamine decreases α2C-adrenoceptor binding of [11C]ORM-13070: a PET study in the primate brain.

Finnema SJ, Hughes ZA, Haaparanta-Solin M, Stepanov V, Nakao R, Varnäs K, Varrone A, Arponen E, Marjamäki P, Pohjanoksa K, Vuorilehto L, Babalola PA, Solin O, Grimwood S, Sallinen J, Farde L, Scheinin M, Halldin C.

Int J Neuropsychopharmacol. 2014 Dec 13;18(3). pii: pyu081. doi: 10.1093/ijnp/pyu081.

46.

Fluorinated analogues of marsanidine, a highly α2-AR/imidazoline I1 binding site-selective hypotensive agent. Synthesis and biological activities.

Wasilewska A, Sączewski F, Hudson AL, Ferdousi M, Scheinin M, Laurila JM, Rybczyńska A, Boblewski K, Lehmann A.

Eur J Med Chem. 2014 Nov 24;87:386-97. doi: 10.1016/j.ejmech.2014.09.083. Epub 2014 Sep 28.

PMID:
25282262
47.

Comparison of simultaneous measurement of mouse locomotor activity by radiotelemetry and photobeam methods.

Streng T, Klemola T, Bastman S, Nevalainen J, Scheinin M.

J Pharmacol Toxicol Methods. 2015 Jan-Feb;71:90-4. doi: 10.1016/j.vascn.2014.09.003. Epub 2014 Sep 16.

PMID:
25219537
48.

Test-retest reliability of (11)C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain.

Lehto J, Virta JR, Oikonen V, Roivainen A, Luoto P, Arponen E, Helin S, Hietamäki J, Holopainen A, Kailajärvi M, Peltonen JM, Rouru J, Sallinen J, Virtanen K, Volanen I, Scheinin M, Rinne JO.

Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):120-7. doi: 10.1007/s00259-014-2899-z. Epub 2014 Sep 9.

PMID:
25201008
49.

Quantitative determination of α(2B)-adrenoceptor-evoked myosin light chain phosphorylation in vascular smooth muscle cells.

Björk S, Huhtinen A, Vuorenpää A, Scheinin M.

J Pharmacol Toxicol Methods. 2014 Sep-Oct;70(2):152-62. doi: 10.1016/j.vascn.2014.07.004. Epub 2014 Aug 7.

PMID:
25109759
50.

¹¹C-ORM-13070, a novel PET ligand for brain α₂C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men.

Luoto P, Suilamo S, Oikonen V, Arponen E, Helin S, Herttuainen J, Hietamäki J, Holopainen A, Kailajärvi M, Peltonen JM, Rouru J, Sallinen J, Scheinin M, Virta J, Virtanen K, Volanen I, Roivainen A, Rinne JO.

Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1947-56. doi: 10.1007/s00259-014-2782-y. Epub 2014 May 17.

PMID:
24838249

Supplemental Content

Loading ...
Support Center